Guangzhou LingSheng Pharma Tech (Link Health) in-licensed greater China rights to a cancer drug from Germany’s 4SC AG (FSE: VSC) in a deal worth up to $84.7 million in upfront and milestone payments. The drug, 4SC-205, inhibits Eg5, the kinesin spindle protein, which plays a key role in cell division. 4SC says 4SC-205 does not have the serious side effects of other Eg5 inhibitors. Link Health will be responsible for China clinical development and commercialization of 4SC-205, which has completed a Phase I trial.
